Meeting
2018 Gastrointestinal Cancers Symposium
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
Authors
Andrea Wang-Gillam
Washington University School of Medicine in St. Louis, St. Louis, MO
Andrea Wang-Gillam , A. Craig Lockhart , Benjamin R. Tan Jr., Rama Suresh , Kian-Huat Lim , Lee Ratner , Ashley Morton , Jess Huffman , Samantha Marquez , Nicolas Boice , David G DeNardo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02546531
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 380)
DOI
10.1200/JCO.2018.36.4_suppl.380
Abstract #
380
Poster Bd #
H17
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
First Author: Andrea Wang-Gillam
Poster
2017 Gastrointestinal Cancers Symposium
Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.
First Author: Andrea Wang-Gillam
Poster
2023 ASCO Annual Meeting
Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Anser Ali Abbas
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang